NMRA SHAREHOLDER INVESTIGATION: SueWallSt Investigates Neumora Therapeutics for Possible Securities Law Violations
Neumora Therapeutics characterized its first failed Phase 3 trial as an "anomaly" and projected 90% statistical power across its navacaprant program -- then both remaining pivotal trials failed, triggering immediate program discontinuation. NEW YORK, June 17, 2026 /PRNewswire/ -- Neumora...
Neumora Therapeutics characterized its first failed Phase 3 trial as an "anomaly" and projected 90% statistical power across its navacaprant program -- then both remaining pivotal trials failed, triggering immediate program discontinuation. NEW YORK, June 17, 2026 /PRNewswire/ -- Neumora...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.